CooperVision Specialty EyeCare celebrated the completed move into its FDA-approved, state-of-the-art manufacturing facility in Gilbert, Arizona with a commemorative event and ribbon-cutting ceremony on May 21, 2021.
The site—which produces Paragon CRT® contact lenses and materials—received FDA approval on its upgraded laboratory in 2019, which now includes a refurbished shipping and warehouse center, as well as a substantially larger specialty lens manufacturing floor. The company also has ambitious plans to expand the facility to more than 45,000 square feet by 2025.
“The recent multi-million dollar investment in the Gilbert facility is a direct result of growing worldwide demand by eye care professionals for Paragon CRT® specialty contact lenses,” said Juan Carlos Aragón, president of CooperVision Specialty EyeCare. “After a four-year transition from the original manufacturing plant in Mesa, we look forward to continuing to provide our employees, our customers, and the local community with the many benefits afforded by these improvements.”
The company celebration was held for all local employees. CooperVision Specialty EyeCare executives including Aragón, Rich Jeffries, Nir Karpick, Carlos Arandia and David Raimondo, as well as CooperVision’s president, Dan McBride, addressed employees with brief speeches about Paragon’s growth throughout the years and the commitment to the specialty contact lens market, ahead of the ribbon-cutting and celebratory activities.
Paragon CRT® orthokeratology (ortho-K) specialty contact lenses are worn overnight and correct myopia during sleeping hours. When patients wake up and remove their lenses they can see clearly throughout the day without the need for glasses or daytime contacts. Myopia has become a global pandemic1. It is estimated that by 2050 half of the world’s population will have myopia2. Paragon CRT® lenses help manage this vision condition and are positively impacting the lives of millions of children and adults around the globe.
CooperVision Specialty EyeCare develops, manufactures, and provides access to an unmatched portfolio of industry-leading soft custom and rigid gas permeable lens designs, including orthokeratology and scleral lenses to address segments such as myopia management, scleral and irregular cornea, and presbyopia management. Its ongoing research and innovative products and services play a leading role in expanding care worldwide. CooperVision Specialty EyeCare is comprised of industry-leading companies including Blanchard, GP Specialists, Paragon, Procornea, Soflex, and No 7.
# # #
1 Akerman, D. (2020, April 15). Is Myopia a Pandemic? Review of Myopia Management. http://reviewofmm.com/is-myopia-a-pandemic/.
2 Holden et al, – Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-1042
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies (“Cooper”) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.